drugset / Trial / NCT00390026

The Avastin vs Visudyne for Neovascular AMD Study

NCT00390026

Phase 3 Withdrawn St. Erik Eye Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The object of the study is to compare the treatment effect of bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration, the leading cause of vision severe loss in the Western world.

Timeline

Start
2006-11
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody Intravitreal
Subject Verteporfin Other / unclassified